Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Receives $20.00 Consensus Target Price from Analysts

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) has been assigned an average recommendation of “Moderate Buy” from the six ratings firms that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $20.00.

A number of brokerages recently issued reports on NBTX. Leerink Partners reissued an “outperform” rating on shares of Nanobiotix in a research report on Tuesday, November 25th. Guggenheim boosted their price target on Nanobiotix from $8.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, February 6th. TD Cowen assumed coverage on Nanobiotix in a research note on Friday, February 6th. They issued a “buy” rating on the stock. Wall Street Zen upgraded Nanobiotix to a “hold” rating in a research note on Saturday, October 25th. Finally, HC Wainwright reissued a “buy” rating on shares of Nanobiotix in a research note on Tuesday, November 4th.

Nanobiotix Price Performance

Shares of Nanobiotix stock opened at $25.34 on Friday. Nanobiotix has a 12 month low of $2.95 and a 12 month high of $30.35. The business has a fifty day simple moving average of $22.02 and a two-hundred day simple moving average of $18.04.

Hedge Funds Weigh In On Nanobiotix

An institutional investor recently bought a new position in Nanobiotix stock. Marshall Wace LLP bought a new stake in shares of Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 9,500 shares of the company’s stock, valued at approximately $220,000. 38.81% of the stock is owned by institutional investors and hedge funds.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.